← Russell 3000 cross-section

GH Guardant Health, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Healthcare

Scale

Market cap
$22.8bn
Revenue TTM
$1.2bn
Net income TTM
$-453m
Free cash flow
$-241m
Composite score
40.3
Sector rank
#417

Valuation

P / E
EV / EBITDA
EV / sales
19.7
FCF yield
-1.05%
Earnings yield vs 10-yr
-6.72pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-38.3%
EBITDA margin
-36.5%
ROE
203.5%
ROIC
-207.5%
Revenue growth
42.7%

Insider activity, last 90 days

Net open-market
$-83.70m
Buyers
1
Sellers
12

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Due to the inherent variability and unpredictability of the reimbursement landscape, including related to the amount that payers reimburse us for any of our tests, we estimate the amount of our oncology and screening revenue to be recognized at the time a test is provided and record revenue adjustments if and when the cash subsequently received differs from the revenue recorded. Our financial results have historically, and will likely continue to, fluctuate significantly based upon the impact of our sales and marketing expense, increase in headcount, and in particular, our various marketing programs around existing and new product introductions. • General and administrative expense . …Guardant Health, Inc., 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →